---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025754"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:56:56.989662+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virpax FY2023 operating loss narrows to $15.2M; cash at $9.1M

## Summary
- Operating loss of $15.2M vs $21.7M in 2022; R&D expenses halved to $5.1M.
- Cash and cash equivalents $9.1M at Dec 31, 2023, down from $19.0M a year earlier.
- Regained Nasdaq compliance on March 18, 2024, after 1-for-10 reverse stock split effective March 1.
- Litigation settlement with Sorrento/Scilex approved by bankruptcy court; initial payment made March 18, 2024.
- CEO change: Anthony Mack resigned Nov 17, 2023; Gerald Bruce appointed CEO and Eric Floyd Chairman.

## SEC filing metadata
- accession: 0001213900-24-025754
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/0001213900-24-025754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/ea0202550-8k_virpax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025754
- JSON: https://secwatch.observer/filing/0001213900-24-025754.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025754.txt

## Key facts
- Earnings Releases
  Virpax Pharmaceuticals, Inc. reported financial results for twelve months ended December 31, 2023.
  - Period: twelve months ended December 31, 2023
  - Result: reported results
  source text: On March 26, 2024, Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/0001213900-24-025754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.